5-Tert-butyl-1,7-naphthyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-Tert-butyl-1,7-naphthyridine
• 英文别名: 5-tert-butyl-1,7-naphthyridine
• 化学式: C₁₂H₁₄N₂
• 分子量: 186.25
• InChiKey: BCZYFVRYCHQRPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS
  申请人：Austin Joel Francis

  公开号：US20140148453A1

  公开（公告）日：2014-05-29

  Disclosed are sulfonamide compounds of Formula (I): or stereoisomers, N-oxides, prodrugs, or pharmaceutically acceptable salts thereof, wherein ring A, R 1 , R 2 , R 3 , R 4 and R 5 are defined herein. Also disclosed are methods of using such compounds in the treatment of conditions related to CYP17 enzyme, such as cancer, and pharmaceutical compositions comprising such compounds.

  本发明涉及式(I)的磺酰胺化合物，或其立体异构体、N-氧化物、前药或其药学上可接受的盐，其中环A、R1、R2、R3、R4和R5如本文所定义。同时，本发明还涉及使用这些化合物治疗与CYP17酶有关的疾病，如癌症，以及包含这些化合物的药物组合物的方法。
• HIF 1-alpha antisense oligonucleotides
  申请人：OliPass Corporation

  公开号：US11319540B2

  公开（公告）日：2022-05-03

  Provided are peptide nucleic acid derivatives targeting a part of the human HIF-1α pre-mRNA. The peptide nucleic acid derivatives potently induce exon skipping to yield splice variants of HIF-1α mRNA in cells, and are useful to treat indications or conditions involving the overexpression of HIF-1α.

  本文提供了以人类 HIF-1α 前 mRNA 的一部分为靶标的多肽核酸衍生物。多肽核酸衍生物能有效诱导外显子跳越，从而在细胞中产生 HIF-1α mRNA 的剪接变体，可用于治疗涉及 HIF-1α 过度表达的适应症或病症。
• HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES
  申请人：OliPass Corporation

  公开号：US20210292767A1

  公开（公告）日：2021-09-23

  Provided are peptide nucleic acid derivatives targeting a part of the human HIF-1α pre-mRNA. The peptide nucleic acid derivatives potently induce exon skipping to yield splice variants of HIF-1α mRNA in cells, and are useful to treat indications or conditions involving the overexpression of HIF-1α.
• NOVEL QUINAZOLINE EGFR INHIBITORS
  申请人：Spectrum Pharmaceuticals, Inc.

  公开号：US20210353627A1

  公开（公告）日：2021-11-18

  This document discloses a novel class of quinazoline EGFR inhibitors. Also disclosed are pharmaceutical compositions thereof and method for treating cancers. Disclosed herein is a novel class of quinazoline compounds which selectively and effectively inhibit the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor (EGFR).
• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20220332713A1

  公开（公告）日：2022-10-20

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.